Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre

Vanderniet, Joel A; Wall, Christie-Lee; Mullins, Anna; London, Kerry; Lim, Lydia; Hibbert, Sally; Briody, Julie; Padhye, Bhavna; Poon, Myra; Biggin, Andrew; Dalla‐Pozza, Luciano; Munns, Craig F

doi:10.1016/j.bone.2022.116395

Cited by 15 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Denosumab induced fatigue, back pain, and arthralgia as treatment-emergent adverse effects. Denosumab treatment has been consistently safe in advanced cancer, in line with the present study [17] , [24] , [26] , [27] . Because of the adverse effects reported here, zoledronic acid treatment was an additional burden for GCTB patients.…”

Section: Discussionsupporting

confidence: 90%

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Yue

Sun

2022

Journal of Bone Oncology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Yue

Sun

2022

Journal of Bone Oncology

View full text Add to dashboard Cite

“…Denosumab is approved for osteoporosis in adults [5], and trials are ongoing for its use in rare bone diseases in adults [6]. Denosumab is used in exceptional circumstances in children [7,8], and there are ongoing trials, although rebound hypercalcaemia on cessation of treatment is a challenging side effect [9]. Therefore, currently bisphosphonates remain the mainstay for treatment in children with bone fragility.…”

mentioning

confidence: 99%

New developments and therapies in pediatric endocrinology

Gevers

Winter

2022

Eur J Pediatr

View full text Add to dashboard Cite

“…This information provides a basis for practicians to perform short-term PATD [ 27 ]. CT, magnetic resonance imaging (MRI), and positron emission tomography (PET) are useful for evaluating tumor response [ 52 , 53 ] and blood supply. Based on the inverse Choi density/size (ICDS) criteria assessed using CT or MRI images before and after treatment with denosumab, the majority of patients with GCTB have a significant tumor response [ 54 ].…”

Section: Dose and Duration Of Therapy With Denosumab Affect The Blood...mentioning

confidence: 99%

Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy

Xiang

Liu

Deng

et al. 2022

Cancers

View full text Add to dashboard Cite

Giant cell tumor of bone (GCTB) is an aggressive non-cancerous bone tumor associated with risks of sarcoma and metastasis. Once malignancy occurs, the prognosis is generally poor. Surgery remains the main treatment for GCTB. Multidisciplinary management is a feasible option for patients wherein surgical resection is not an option or for those with serious surgery-related complications. Denosumab is an anti-nuclear factor kappa B ligand approved for the treatment of postmenopausal women with osteoporosis, bone metastases, and advanced or inoperable GCTB. However, the guidelines for treating GCTB are unclear; its short-term efficacy and safety in inoperable patients have been demonstrated. Lengthier therapies (high cumulative doses) or pre-operative adjuvant therapy may be associated with severe complications and high local recurrence rates. Short-term administration helps attain satisfactory local control and functionality. As a result, lately, the impact of different doses and lengths of treatment on the efficacy of denosumab in GCTB treatment, the incidence of complications, and recurrence rates have gained attention. The efficacy and safety of denosumab against GCTB, its impact on imaging assessment, related complications, and recurrence of GCTB were previously reviewed. For further research direction, this paper reviews the progress of studies evaluating the impact of the dose and duration of denosumab therapy for GCTB.

show abstract

Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre

Cited by 15 publications

References 31 publications

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

New developments and therapies in pediatric endocrinology

Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy

Contact Info

Product

Resources

About